Synthetic Kills Some Cancer Tumors
Posted on: Monday, 12 November 2007, 21:00 CST
A synthetic compound has been shown to be effective in treating human lung-cancer tumors grown in mice, researchers at a Dallas medical center reported.
The findings, appearing in the latest edition of Cancer Cell, suggested the compound could be used in targeted therapies for lung and other cancers, researchers at UT Southwestern Medical Center in Dallas said in a news release.
The synthetic compound mimics the action of a naturally occurring cellular protein called Smac, which plays a major role in the normal self-destruction of a cell, researchers said.
We found that certain kinds of lung-cancer cells were sensitive to this compound, which sends a signal to cancer cells to self-destruct, said Dr. Xiaodong Wang, professor of biochemistry at UT Southwestern and senior author of the study.
Wang's research group tested 50 human non-small-cell lung-cancer cell lines and found that 22 percent of them were sensitive to the Smac protein. They also found that the Smac mimic was effective against some types of breast cancer and melanoma cells.
The apparent ability of a Smac mimetic, as a single agent, to induce cell death in nearly one-quarter of lung-cancer cell lines tested was quite remarkable, Wang said.
Source: United Press International
Related Articles
- Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
- New Pfizer Data Presented on CP-751,871 Across Non-Small Cell Lung Cancer and Ewing's Sarcoma
- New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients With Non-Small Cell Lung Cancer
- View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date Inside 'Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents'
- Vion Initiates Phase II Trial of Cloretazine(R) in Small Cell Lung Cancer
- Comparison of Different Methods for Delineation of ^Sup 18^F-FDG PET- Positive Tissue for Target Volume Definition in Radiotherapy of Patients With Non-Small Cell Lung Cancer
- The Impact of Smoking Status on the Behavior and Survival Outcome of Patients With Advanced Non-Small Cell Lung Cancer*: A Retrospective Analysis
- Point Therapeutics Achieves Interim Tumor Response Criteria in Phase 2 Non-Small Cell Lung Cancer Study; Company Advances Talabostat to Second Stage of Study
- Comparative Genomic Hybridization (CGH) Detects Common and Distinct Aberrations in Non-Small Cell Lung Tumors of Different Histology
- New Targets for Detection and Treatment of Small Cell Lung Cancer*
 |
 |
User Comments (0)
RSS Feeds